Syngeva BioPharma, Inc. Series X $12M

Posted in Q - 4Q09, R - NORTH EAST, X - Antibody, X - Biosimilars, X - Cytokine, X - Therapeutic Platform, XX - MA

Synageva BioPharma (Waltham, MA) a clinical-stage biopharma and developer of the Synageva Expression Platform, an integrated platform of vectors and protein production, processing and purification systems used to develop their pipeline of monoclonal antibodies, cytokines, and biosimilars, closed a $12M Series X financing bringing the total round to $45M. Participants include New Leaf Venture Partners, [...]

May

2009

Synageva BioPharma Corp.: Series X $33M

Posted in I - Series F, Q - 2Q09, R - NORTH EAST, X - Antibody, X - Biosimilars, X - Cytokine, X - Therapeutic Platform, XX - MA

Synageva BioPharma (Waltham, MA) a clinical-stage biopharma and developer of the Synageva Expression Platform, an integrated platform of vectors and protein production, processing and purification systems used to develop their pipeline of monoclonal antibodies, cytokines, and biosimilars, closed a $33M Series X financing. Participants inlcude Baker Brothers Investments, Tullis Health Investors, Four Partners, Yasuda Enterprise [...]

Nov

2008

Itero Biopharmaceuticals, Inc.: Series A $21M

Posted in I - Series A, Q - 2Q08, R - WEST, X - Biosimilars, X - Generics

Itero Biopharmaceuticals (San Mateo, CA) focused on novel and follow-on protein and antibody therapeutics, closed a $21M Series A financing. Participants include SV Life Sciences, Panorama Capital and VenturEast.

to top of page...